Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
Conditions
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Classic Hodgkin Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Anaplastic Large Cell Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Refractory Mycosis Fungoides
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
- BIOLOGICAL: Anti-CD30/CD16A Monoclonal Antibody AFM13
- DRUG: Cyclophosphamide
- DRUG: Fludarabine
- DRUG: Fludarabine Phosphate
- BIOLOGICAL: Genetically Engineered Lymphocyte Therapy
Sponsor
M.D. Anderson Cancer Center